**The Anti-Atherogenic Effects of Lycopene**

Amany M. M. Basuny

488 Lipoproteins – Role in Health and Diseases

Med. Chem. 16: 4345-4360.

Dis. 18: 88-95.

[50] Lindi V, Schwab U, Louheranta A, Vessby B, Hermansen K, Tapsell L, Riccardi G, Rivellese AA, Laakso M, Uusitupa MI (2008) The G-250A polymorphism in the hepaticlipase gene promoter is associated with changes in hepatic lipase activity and LDL cholesterol: The KANWU Study. KANWU Study Group. Nutr. Metab. Cardiovasc.

[51] Kolovou GD, Anagnostopoulou KK, Kostakou PM, Mikhailidis DP (2009) Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs. Curr.

[52] Behre HM, Simoni M, Nieschlag E (1997) Strong association between serum levels of

[53] Huang Y, Liu XQ, Rall SC, Taylor JM, von Eckardstein A, Assmann G, Mahley RW (1998) Overexpression and accumulation of apolipoprotein E as a cause of

[54] Xie X, Zhu Y (2007) Insights into cholesterol efflux in vascular endothelial cells.

[55] Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M (2008) Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alphamigrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL

leptin and testosterone in men. Clin. Endocrinol. 47: 237–240.

hypertriglyceridemia. J. Biol. Chem. 273: 26388-26393.

Cardiovasc Hematol Disord Drug Targets. 7: 127-134.

remodeling. Atherosclerosis. 200: 329-335.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/48134
